Centers for Disease Control and Prevention; Centers for Medicare & Medicaid Services. Estimated hypertension prevalence, treatment, and control among US adults. Million Hearts. Accessed June 1, 2024. https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html

• PubMed
Centers for Disease Control and Prevention; Centers for Medicare & Medicaid Services. Estimated hypertension prevalence, treatment, and control among US adults. Million Hearts. Accessed June 1, 2024. https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html)| false
• Search Google Scholar
• Export Citation

Schlaich MP, et al.; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): A multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022; 400:1927–1937. doi: 10.1016/S0140-6736(22)02034-7

• PubMed
Schlaich MP, ; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): A multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022; 400:1927–1937. doi: 10.1016/S0140-6736(22)02034-7)| false
• Search Google Scholar
• Export Citation

Bakris GL, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:2219–2229. doi: 10.1056/NEJMoa2025845

• PubMed
Bakris GL, ; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:2219–2229. doi: 10.1056/NEJMoa2025845)| false
• Search Google Scholar
• Export Citation

Pitt B, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385:2252–2263. doi: 10.1056/NEJMoa2110956

• PubMed
Pitt B, ; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385:2252–2263. doi: 10.1056/NEJMoa2110956)| false
• Search Google Scholar
• Export Citation

Bakris G, et al.; BLOCK-CKD Study Group. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the BLOCK-CKD study. Hypertension 2021; 78:74–81. doi: 10.1161/HYPERTENSIONAHA.121.17073

• PubMed
Bakris G, ; BLOCK-CKD Study Group. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the BLOCK-CKD study. Hypertension 2021; 78:74–81. doi: 10.1161/HYPERTENSIONAHA.121.17073)| false
• Search Google Scholar
• Export Citation

Pivonello R, et al.; LINC 3 investigators. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): A multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 2020; 8:748–761. doi: 10.1016/S2213-8587(20)30240-0

• PubMed
Pivonello R, ; LINC 3 investigators. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): A multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 2020; 8:748–761. doi: 10.1016/S2213-8587(20)30240-0)| false
• Search Google Scholar
• Export Citation

Freeman MW, et al.; BrigHTN Investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 2023; 388:395–405. doi: 10.1056/NEJMoa2213169

• PubMed
Freeman MW, ; BrigHTN Investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 2023; 388:395–405. doi: 10.1056/NEJMoa2213169)| false
• Search Google Scholar
• Export Citation

Laffin LJ, et al.; Target-HTN Investigators. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: The Target-HTN randomized clinical trial. JAMA 2023; 330:1140–1150. doi: 10.1001/jama.2023.16029

• PubMed
Laffin LJ, ; Target-HTN Investigators. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: The Target-HTN randomized clinical trial. JAMA 2023; 330:1140–1150. doi: 10.1001/jama.2023.16029)| false
• Search Google Scholar
• Export Citation

Bakris GL, et al.; KARDIA-1 Study Group. RNA interference with zilebesiran for mild to moderate hypertension: The KARDIA-1 randomized clinical trial. JAMA 2024; 331:740–749. doi: 10.1001/jama.2024.0728

• PubMed
Bakris GL, ; KARDIA-1 Study Group. RNA interference with zilebesiran for mild to moderate hypertension: The KARDIA-1 randomized clinical trial. JAMA 2024; 331:740–749. doi: 10.1001/jama.2024.0728)| false
• Search Google Scholar
• Export Citation

Bavry AA. Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension—KARDIA-2. Presented at: American College of Cardiology Annual Scientific Session (ACC.24); April 7, 2024; Atlanta, GA. https://www.acc.org/latest-in-cardiology/clinical-trials/2024/04/05/04/26/kardia-2

• PubMed
Bavry AA. Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension—KARDIA-2. Presented at: American College of Cardiology Annual Scientific Session (ACC.24); April 7, 2024; Atlanta, GA. https://www.acc.org/latest-in-cardiology/clinical-trials/2024/04/05/04/26/kardia-2)| false
• Search Google Scholar
• Export Citation